KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Shares Issued (2023 - 2025)

Biocryst Pharmaceuticals' Shares Issued history spans 9 years, with the latest figure at $657000.0 for Q4 2025.

  • For Q4 2025, Shares Issued rose 212.12% year-over-year to $657000.0; the TTM value through Dec 2025 reached $9.1 million, up 164.66%, while the annual FY2025 figure was $9.1 million, 164.66% up from the prior year.
  • Shares Issued reached $657000.0 in Q4 2025 per BCRX's latest filing, down from $2.6 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $5.1 million in Q1 2023 to a low of -$586000.0 in Q4 2024.
  • Average Shares Issued over 3 years is $1.7 million, with a median of $1.7 million recorded in 2023.
  • Peak YoY movement for Shares Issued: tumbled 1602.56% in 2024, then surged 1195.83% in 2025.
  • A 3-year view of Shares Issued shows it stood at $39000.0 in 2023, then crashed by 1602.56% to -$586000.0 in 2024, then soared by 212.12% to $657000.0 in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Shares Issued are $657000.0 (Q4 2025), $2.6 million (Q3 2025), and $3.4 million (Q2 2025).